{"entity":{"id":"umoja-biopharma","kind":"company","name":"Umoja Biopharma","aka":[],"tldr":"In vivo CAR-T company using lentiviral vectors (VivoVec); first CD22-directed in vivo CAR-T cleared for US trials in 2026.","summary":"Umoja Biopharma, based in Seattle, is an in vivo CAR-T company that uses lentiviral vectors, its VivoVec platform, to make CAR-T cells inside the body, and in 2026 its CD22-directed candidate became the first of its kind cleared for US trials. UB-VV111 targets CD19 and holds Fast Track designations, UB-VV400 targets CD22 and had its IND cleared in 2026, both for relapsed or refractory B-cell malignancies, and first clinical data from an investigator-initiated UB-VV400 trial in China are expected in the second half of 2026. OnCo links it to diffuse large B-cell lymphoma and acute lymphoblastic leukaemia, to in vivo CAR-T, to CD19 as a target, and to ideas on in vivo CAR-T as a vial on the shelf. Manufacturing cost and time for living medicines is the bottleneck it addresses. Whether viral in vivo delivery is safe enough for repeat dosing is the open question.","asOf":"2026-09-04","links":[{"label":"UB-VV400 IND clearance","url":"https://www.umoja-biopharma.com/news/umoja-biopharma-announces-fda-clearance-of-ind-application-for-ub-vv400-the-industrys-first-known-cd22-directed-in-vivo-car-t-cell-therapy-for-relapsed-refractory-b-cell-malignancies/"}],"tags":["frontier"],"related":[],"cancers":["dlbcl","all-leukemia"],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Seattle, WA","country":"US","companyType":"cell-therapy","website":"https://www.umoja-biopharma.com","investors":[],"funding":[]},"route":"/companies/umoja-biopharma/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"},{"id":"dlbcl","kind":"cancer","name":"Diffuse large B-cell lymphoma","route":"/cancers/dlbcl/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"bottleneck":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/"}],"idea":[{"id":"idea-reg-in-vivo-cart-off-the-shelf-vial","kind":"idea","name":"In vivo CAR-T as a vial on the shelf: a cost and access trial in lymphoma","route":"/ideas/idea-reg-in-vivo-cart-off-the-shelf-vial/"},{"id":"idea-moon-in-vivo-cart-generic-price","kind":"idea","name":"In vivo CAR-T manufactured and priced like a generic biologic","route":"/ideas/idea-moon-in-vivo-cart-generic-price/"}],"company":[{"id":"mpm-bioimpact","kind":"company","name":"MPM BioImpact","route":"/companies/mpm-bioimpact/"}]}}